$0.06 EPS Expected for PDL BioPharma, Inc. (PDLI)

April 17, 2018 - By Michael Collier

PDL BioPharma, Inc. (NASDAQ:PDLI) LogoInvestors sentiment decreased to 1.13 in 2017 Q4. Its down 0.37, from 1.5 in 2017Q3. It dived, as 18 investors sold PDL BioPharma, Inc. shares while 52 reduced holdings. 26 funds opened positions while 53 raised stakes. 134.59 million shares or 2.55% more from 131.24 million shares in 2017Q3 were reported.
Ironwood Financial Ltd Liability Company has invested 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI). Clarivest Asset Mgmt Lc has invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Zeke Capital Limited Liability Company holds 0% or 17,194 shares in its portfolio. State Board Of Administration Of Florida Retirement System owns 141,207 shares. 293,040 were reported by Macquarie Grp Ltd. New Jersey-based Prudential Fin has invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Bnp Paribas Arbitrage Sa reported 69,897 shares stake. Wealthtrust Axiom Limited Liability invested in 33,000 shares. Parallax Volatility Advisers Limited Partnership accumulated 0% or 24,444 shares. Btc Management Inc invested in 0.04% or 91,600 shares. State Of Wisconsin Investment Board holds 122,000 shares or 0% of its portfolio. First Eagle Investment Management Ltd Liability Co reported 2,800 shares. Dekabank Deutsche Girozentrale holds 0% in PDL BioPharma, Inc. (NASDAQ:PDLI) or 195,610 shares. Whittier, a California-based fund reported 20 shares. Denali Advsr Limited Liability Co holds 330 shares or 0% of its portfolio.

Analysts expect PDL BioPharma, Inc. (NASDAQ:PDLI) to report $0.06 EPS on May, 2.They anticipate $0.02 EPS change or 25.00 % from last quarter’s $0.08 EPS. PDLI’s profit would be $9.23M giving it 12.52 P/E if the $0.06 EPS is correct. After having $0.17 EPS previously, PDL BioPharma, Inc.’s analysts see -64.71 % EPS growth. The stock increased 0.17% or $0.005 during the last trading session, reaching $3.005. About 309,624 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has risen 39.51% since April 17, 2017 and is uptrending. It has outperformed by 27.96% the S&P500.

PDL BioPharma, Inc. (NASDAQ:PDLI) Ratings Coverage

Among 2 analysts covering PDL BioPharma (NASDAQ:PDLI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. PDL BioPharma had 2 analyst reports since October 26, 2017 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Friday, November 3. Cowen & Co maintained the stock with “Hold” rating in Thursday, October 26 report.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $462.21 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 4.23 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.